Advanced search    

Search: authors:"Debra Fayter"

7 papers found.
Use AND, OR, NOT, +word, -word, "long phrase", (parentheses) to fine-tune your search.

Pembrolizumab for Treating Relapsed or Refractory Classical Hodgkin Lymphoma: An Evidence Review Group Perspective of a NICE Single Technology Appraisal

of NICE or the Department of Health. Any errors are the responsibility of the authors. Author Contributions Debra Fayter, Rob Riemsma, Nigel Armstrong and Jos Kleijnen critiqued the clinical ... further project information (https://www.nihr.ac.uk/funding-and-support/funding-for-research-studies/funding-programmes/health-technologyassessment). Conflicts of interest Sabine E. Grimm, Debra Fayter

Obinutuzumab in Combination with Chemotherapy for the First-Line Treatment of Patients with Advanced Follicular Lymphoma

critiqued the clinical effectiveness methods and evidence. Isaac Corro Ramos acted as health economic project lead and critiqued the company’s economic evaluation. Debra Fayter and Vanesa Huertas Carrera

Ribociclib with an Aromatase Inhibitor for Previously Untreated, HR-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal

systematic reviewer on this assessment and critiqued the clinical effectiveness methods and evidence. Debra Fayter and Piet Portegijs acted as systematic reviewers and critiqued the clinical effectiveness ... Health Service or the Department of Health. Conflict of interest Nasuh C. Büyükkaramikli, Saskia de Groot, Rob Riemsma, Debra Fayter, Nigel Armstrong, Piet Portegijs, Steven Duffy, Jos Kleijnen and

Trifluridine–Tipiracil for Previously Treated Metastatic Colorectal Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal

The National Institute for Health and Care Excellence (NICE) invited Servier, the company manufacturing trifluridine and tipiracil (T/T; trade name: Lonsurf®), to submit evidence for the clinical and cost effectiveness of T/T compared with best supportive care (BSC) for metastatic colorectal cancer (third-line or later). Kleijnen Systematic Reviews Ltd (KSR), in collaboration...

Pomalidomide with Dexamethasone for Treating Relapsed and Refractory Multiple Myeloma Previously Treated with Lenalidomide and Bortezomib: An Evidence Review Group Perspective of an NICE Single Technology Appraisal

. Conflict of interest Nasuh C. Bu¨ yu¨kkaramikli, Saskia de Groot, Debra Fayter, Robert Wolff, Nigel Armstrong, Lisa Stirk, Gill Worthy, Fernando Albuquerque de Almeida, Jos Kleijnen and Maiwenn J. Al have no

The harvest plot: A method for synthesising evidence about the differential effects of interventions

Background One attraction of meta-analysis is the forest plot, a compact overview of the essential data included in a systematic review and the overall 'result'. However, meta-analysis is not always suitable for synthesising evidence about the effects of interventions which may influence the wider determinants of health. As part of a systematic review of the effects of population...

Increasing participation of cancer patients in randomised controlled trials: a systematic review

Background There are many barriers to patient participation in randomised controlled trials of cancer treatments. To increase participation in trials, strategies need to be identified to overcome these barriers. Our aim was to assess the effectiveness of interventions to overcome barriers to patient participation in randomised controlled trials (RCTs) of cancer treatments...